Abstract:Chinese herbal medicines (CHM) are frequently used to treat different types of inflammatory diseases and 15-Lipoxygenase (15-LOX) is a critical target enzyme for treating various inflammatory diseases. In this study, natural 15-LOX inhibitors were identified in CHM using an approach of virtual screening combined with the biological assays. First, an in-house Chinese medicine database containing 360 compounds was screened using a virtual screening approach based on pharmacophore and molecular docking to uncover several novel potential 15-LOX inhibitors. Secondly, the inhibitory effect of virtual screening hits against the 15-LOX enzyme was validated in an in vitro enzyme inhibition assay. Then, a tumor necrosis factor-alpha (TNF-alpha) release assay was carried out to explore the anti-inflammatory response of the active compounds. Furthermore, molecular dynamics (MD) simulation and binding free energy calculation were applied to analyze the process of inhibitors binding and also compared the mode of binding of the inhibitors by using the Molecular Mechanics-Generalized Born Surface Area (MM/GBSA) method. Finally, licochalcone B and eriodictyol were confirmed as inhibitors of the 15-LOX enzyme with IC50 values of 9.67 and 18.99 mu M, respectively. In vitro cell-based assay showed that licochalcone B and eriodictyol inhibited the release of TNF-alpha factor in RAW264.7 cells stimulated by lipopolysaccharides (LPS) in a dose dependent manner. Molecular dynamics and binding free energy analysis showed that the two 15-LOX-ligand systems immediately attained equilibrium with almost 1 angstrom fluctuation, the calculated binding free energies were found around -18.89 and -12.96 kcal/mol for licochalcone B and eriodictyol, respectively. Thr412, Arg415, Val420, Thr429, Ile602 and Trp606 were the main amino acid residues for the inhibition of 15-LOX enzyme activity. The current study confirms that licochalcone B and eriodictyol are 15-LOX inhibitors and can suppress the release of the TNF-alpha factor in RAW264.7 cells stimulated by LPS, thus providing a basis for the follow-up research and development for 15-LOX inhibitors.

Discovery of Anti-Hypercholesterolemia Agents Targeting LXRα from Marine Microorganism-Derived Natural Products

Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

Discovery of novel liver X receptor inverse agonists as lipogenesis inhibitors

Discovery of Novel N,N-3-phenyl-3-benzylaminopropionanilides As Potent Inhibitors of Cholesteryl Ester Transfer Protein in Vivo.

Discovery of Tissue Selective Liver X Receptor Agonists for the Treatment of Atherosclerosis Without Causing Hepatic Lipogenesis.

Design, Synthesis and Biological Evaluation of N,N-3-phenyl-3-benzylaminopropanamide Derivatives As Novel Cholesteryl Ester Transfer Protein Inhibitor

Discovery Of Selective Farnesoid X Receptor Agonists For The Treatment Of Hyperlipidemia From Traditional Chinese Medicine Based On Virtual Screening And In Vitro Validation

In Silico Identification of Small Molecules As Novel LXR Agonists for the Treatment of Cardiovascular Disease and Cancer

Diterpenoid, Steroid, And Triterpenoid Agonists Of Liver X Receptors From Diversified Terrestrial Plants And Marine Sources

Identification of A Novel Partial Agonist of Liver X Receptor Alpha (lxr Alpha) Via Screening

The discovery of a new potent FXR agonist based on natural product screening

Lipid Accumulation Inhibitory Activities of Novel Isoxazole-Based Chenodeoxycholic Acids: Design, Synthesis and Preliminary Mechanism Study

Identification of Novel Sphydrofuran-Derived Derivatives with Lipid-Lowering Activity from the Active Crude Extracts of Nocardiopsis sp. ZHD001

Identification of a Novel Partial Agonist of Liver X Receptor Α (lxrα) Via Screening.

Synthesis of liver X receptor agonists from hydeoxycholic acid

Computer-Simulated Screening-Based Discovery of Three Potential LXR Agonists from Chemical Components Derived from Huanglian Jiedu Decoction

Discovery of Natural Products As Novel and Potent FXR Antagonists by Virtual Screening.

Structure Optimization of 12β-O-γ-Glutamyl Oleanolic Acid Derivatives Resulting in Potent FXR Antagonist/Modulator for NASH Therapy

Discovery of novel and selective farnesoid X receptor antagonists through structure-based virtual screening, preliminary structure-activity relationship study, and biological evaluation

Discovery of natural 15-LOX small molecule inhibitors from Chinese herbal medicine using virtual Screening, biological evaluation and molecular dynamics studies